Symptoms: hypoglycemia may develop.
Treatment: mild hypoglycemia can be eliminated by the patient himself, taking sugar or carbohydrate-rich foods. Therefore, patients with diabetes are recommended to carry sugar, sweets, cookies or sweet fruit juice at all times.
In severe cases, when the patient loses consciousness, a 40% dextrose solution is administered intravenously, v / m, p / k, v / v-glucagon. After regaining consciousness, the patient is recommended to take a meal rich in carbohydrates to prevent the recurrence of hypoglycemia.
increased individual sensitivity to insulin or any other of the components of the drug,
hypoglycemia.
The hypoglycemic effect of insulin is enhanced by oral hypoglycemic drugs, MAO inhibitors, ACE inhibitors, carbonic anhydrase inhibitors, non-selective beta-blockers, bromocriptine, octreotide, sulfonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, lithium preparations, preparations containing ethanol.
The hypoglycemic effect of insulin is weakened by oral contraceptives, corticosteroids, thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, danazol, clonidine, BCC, diazoxide, morphine, phenytoin, nicotine.
Under the influence of reserpine and salicylates, both weakening and strengthening of the effect of the drug is possible.
Caused by the effect on carbohydrate metabolism: hypoglycemic conditions (pallor of the skin, increased sweating, palpitations, tremors, hunger, agitation, paresthesia in the mouth, headache). Severe hypoglycemia can lead to the development of hypoglycemic coma.
Allergic reactions: rarely-skin rash, Quincke's edema, extremely rarely-anaphylactic shock.
Local reactions: hyperemia, swelling and itching at the injection site, with prolonged use — lipodystrophy at the injection site.
Other: edema, transient refractive errors (usually at the beginning of therapy).
type 1 diabetes mellitus,
type 2 diabetes mellitus: stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (during combination therapy), intercurrent diseases.
Biosulin 30/70 — Human insulin produced using recombinant DNA technology. It is a combination of short-and medium-duration insulins in a ratio of 30: 70. It interacts with a specific receptor of the outer cytoplasmic membrane of cells and forms an insulin-receptor complex that stimulates intracellular processes, including.tsch. synthesis of a number of key enzymes (including hexokinase, pyruvate kinase, glycogen synthetase). Decreasing the amount of glucose in the blood due to t.tsch. by increasing its intracellular transport, increasing absorption and assimilation by tissues, stimulating lipogenesis, glycogenogenesis, and reducing the rate of glucose production by the liver
The duration of action of insulin preparations is mainly due to the rate of absorption, which depends on several factors (for example, the dose, method and place of administration), and therefore the profile of the action of insulin is subject to significant fluctuations, both in different people and in the same person.
Action Profile at the n / a injection (approximate figures): the beginning of the action after 30 minutes, the maximum effect — in the interval between 2 and 8 hours, the duration of action-up to 24 hours.
The fullness of the suction and the beginning of the effect of insulin dependent including from the injection site (abdomen, thigh, buttocks), the dose (how much insulin), insulin concentrations of the drug. It is distributed unevenly through the tissues: it does not penetrate the placental barrier and into breast milk. It is destroyed by insulinase, mainly in the liver and kidneys. It is excreted by the kidneys (30-80%).
Biosulin 30/70
Insulin Biphasic [human Biosynthetic]
P/c, in the thigh. Injections can also be made in the anterior abdominal wall, buttock or the area of the deltoid muscle of the shoulder.
It is necessary to change the injection sites within the anatomical area to prevent the development of lipodystrophy.
The dose of the drug is determined by the doctor individually in each specific case, based on the level of glucose in the blood. On average, the daily dose of the drug ranges from 0.5 to 1 IU / kg (depending on the individual characteristics of the patient and the level of glucose in the blood).
The temperature of the injected insulin should correspond to room temperature.
A10AD01 Human Insulin
